Conrad Curdin, Nestle Frank O
Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland.
Curr Opin Mol Ther. 2003 Aug;5(4):405-12.
Dendritic cell (DC)-based cancer immunotherapy has been shown to be safe and feasible. In clinical pilot studies, DCs primed with tumor antigens have successfully been used to induce tumor-specific immunity and obtain some clinical responses in cancer patients. Even though many advances have been achieved over the past years, we are still far from a unifying therapy concept. This review will discuss the current research driving the rapidly growing field of DC-based cancer immunotherapy and highlight some recent progress related to critical issues such as DC preparation, choice and loading of antigen, and the route of administration.
基于树突状细胞（DC）的癌症免疫疗法已被证明是安全可行的。在临床试点研究中，用肿瘤抗原致敏的DC已成功用于诱导肿瘤特异性免疫，并在癌症患者中获得了一些临床反应。尽管在过去几年中取得了许多进展，但我们距离统一的治疗概念仍有很大差距。本综述将讨论推动基于DC的癌症免疫疗法快速发展领域的当前研究，并强调与DC制备、抗原选择和负载以及给药途径等关键问题相关的一些最新进展。
